Performance and impact of a rapid method combining mass spectrometry and direct antimicrobial susceptibility testing on treatment adequacy of patients with ventilator-associated pneumonia  by Le Dorze, M. et al.
ORIGINAL ARTICLE BACTERIOLOGYPerformance and impact of a rapid method combining mass spectrometry
and direct antimicrobial susceptibility testing on treatment adequacy of
patients with ventilator-associated pneumoniaM. Le Dorze1, N. Gault2,3,4, A. Foucrier1, E. Ruppé5,6, B. Mourvillier1,6, P. L. Woerther5, G. Birgand6,7, P. Montravers8, M. P. Dilly9,
F. Tubach2,3,4, A. Andremont5,6, J. F. Timsit1,6, M. Wolff1,6 and L. Armand-Lefèvre5,6
1) Réanimation médicale et infectieuse, 2) Département Epidémiologie et Recherche Clinique, AP-HP, Hôpital Bichat, 3) INSERM CIE 801, 4) UMR 1123 ECEVE,
Université Paris Diderot, Sorbonne Paris Cité, 5) Laboratoire de Bactériologie, AP-HP, Hôpital Bichat, 6) UMR 1137, INSERM, IAME, Université Paris Diderot,
Sorbonne Paris Cité, 7) Unité hospitalière de lutte contre les infections nosocomiales, 8) Réanimation chirurgicale and 9) Réanimation chirurgicale cardio-vasculaire,
AP-HP, Hôpital Bichat, Paris, FranceAbstractInappropriate antibiotic therapy in ventilator-associated pneumonia (VAP) is associated with increased mortality. Using broad-spectrum
antibiotics for 48 h until the results of conventional cultures and antimicrobial susceptibility testing (AST) are available, may promote
the emergence of drug-resistant bacteria. Performing AST directly on clinical respiratory samples would hasten the process by at least
24 h. Here, we analysed the diagnostic performance of a rapid method combining mass spectrometry and direct AST (DAST), and
compared it with the conventional method (mass spectrometry with conventional AST (CAST)). Additionally, we assessed its potential
impact on antimicrobial use in patients. Over a period of 18 months, the two methods were performed on 85 bronchoalveolar lavages
obtained from intensive care unit patients with suspected VAP, and in which Gram-negative bacilli were observed on direct
examination. Only the CAST results were reported to the clinicians. DAST produced useable results in 85.9% of the patients. The
sensitivity and negative predictive values of DAST were 100% for all antibiotics tested, except gentamicin (97.1%, (95% CI 93.3–101)
and 97.4% (93.7–101), respectively) and amikacin (88.9% (81.7–96.1) and 96.4% (92.1–100.7), respectively), compared with CAST.
Speciﬁcity and positive predictive values ranged from 82.9 (74.2–91.5) to 100%, and from 86.4 (78.5−94.2) to 100%, respectively. If the
DAST results had been reported to the clinicians, treatment could have been optimized 24 h earlier in 35/85 (41.2%) patients, with 17
carbapenem patient-days saved. Overall, routine use of the DAST method could help optimize earlier antibiotic treatment in patients
with suspected VAP.
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p://dx.doi.org/10.1016/j.cmi.2014.12.007IntroductionVentilator-associated pneumonia (VAP) is the most common
hospital-acquired infection in intensive care units (ICU),
affecting up to 30% of ventilated patients. VAP is associated with
high morbidity and mortality rates (20–50%) [1,2], especially if
the administration of appropriate antibiotics is delayed [3,4].
Therefore, the use of empirical broad-spectrum antibiotics isious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Le Dorze et al. Direct antimicrobial susceptibility testing in VAP 468.e2advocated [5–7]. However, broad-spectrum antibiotic therapy
leads to the emergence of multidrug-resistant bacteria [8].
Currently, diagnosis of VAP relies on the quantitative culture of
protected respiratory specimens such as bronchoalveolar
lavage (BAL) or mini-BAL [9]. Results of conventional antibiotic
susceptibility testing (CAST) using classical microbiology
methods can be obtained only 48–72 h after sampling, during
which time treatment can only be empirical, based on the re-
sults of direct examination of the sample. This delay in treat-
ment might be reduced by performing antimicrobial
susceptibility testing (AST) directly on the clinical specimen
[10–12], which can provide results 24 h earlier than CAST.
However, direct AST (DAST) lacks technical standardization,
and, to the best of our knowledge, its impact on potential
antibiotic optimization has not been fully evaluated [13]. In this
study, we assessed the diagnostic performance of the rapid
method (combination of DAST and mass spectrometry-based
bacterial identiﬁcation) compared with the conventional
method (CAST and mass spectrometry-based bacterial identi-
ﬁcation) for Gram-negative bacilli (GNB) isolated from BAL or
mini-BAL in ICU patients with suspected VAP. We also ana-
lysed the potential impact of the results of the rapid method on
early adaptation and de-escalation of antimicrobial therapy.Materials and methodsThis study was performed, between May 2011 and October
2012, in the 25-bedmedical and infectious diseases ICU (M-ICU),
the 17-bed surgical ICU (S-ICU), and the 15-bed cardio-surgical
ICU (CS-ICU) of Bichat-Claude Bernard University Hospital
(Paris, France), a large secondary-care teaching hospital.
BAL and mini-BAL, obtained from patients with suspected
VAP, and in which GNB were seen on direct smear examina-
tion, were tested using both CAST and DAST.
Microbiology
Direct smear examination using Gram staining and quantitative
culture were performed for all samples as described previously
[9]. Microbiologically conﬁrmed cases of VAP were deﬁned as
thosewith104CFU/mL in BALsor103CFU/mL inmini-BALs.
In both CAST and DAST, bacterial identiﬁcation was per-
formed using mass spectrometry (Biotyper, Bruker Daltonics,
Germany). In CAST, antibiotic susceptibility was performed using
the disc diffusion method on Mueller–Hinton media (Bio-Rad,
Marnes-la-Coquette, France) from colonies isolated after pri-
mary culture, according to the recommendations of the French
Society of Microbiology (SFM; http://www.sfm-microbiologie.
org). We tested susceptibility to ticarcillin, ticarcillin/clavulanic
acid, piperacillin, piperacillin/tazobactam, ceftazidime, aztreonam,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inimipenem, gentamicin, amikacin and oﬂoxacin for both enter-
obacteria and non-fermenters. Susceptibility to amoxicillin,
amoxicillin/clavulanic acid, cefoxitin, cefotaxime, cefepime and
nalidixic acid was assessed for enterobacteria only, and to mer-
openem and ciproﬂoxacin for non-fermenters only. The results
were categorized as susceptible, intermediate or resistant ac-
cording to the recommendations of SFM and immediately re-
ported to the clinicians. The results of CASTwere available 2 days
after the sample had been collected.
In DAST, the antibiotic susceptibility was assessed directly by
streaking Mueller–Hinton plates with a dry-cotton swab
immersed in the specimen, after adjusting the inoculum on the
basis of the quantity of GNB present on direct smear exami-
nation. When <1 GNB per ﬁeld (×1000) was present, the
clinical sample was used undiluted. When 1–10, 10–100 and
>100 GNB per ﬁeld were observed, dilutions of 10−1, 10−2 and
10−3, respectively, were used. Susceptibility testing was limited
to ticarcillin, ticarcillin/clavulanic acid, piperacillin, piperacillin/
tazobactam, cefoxitin, cefotaxime, ceftazidime, cefepime,
aztreonam, imipenem, meropenem, gentamicin, amikacin, nali-
dixic acid, oﬂoxacin and ciproﬂoxacin in all instances. Reading
was performed after incubation at 37°C, for 18–24 h. Cate-
gorization was made according to the recommendations of
SFM. In the case of mixed cultures, susceptibility to each anti-
biotic was determined by analysing the inhibition diameters of
the less susceptible bacteria. The results of DAST were avail-
able one day after the sample had been collected, but were not
reported to the physician in charge of the patient.
Diagnostic performance
To compare the results of CAST and DAST, those classiﬁed as
intermediate and resistant were considered a single group and
labelled as resistant. CAST results were considered the refer-
ence standard.
DAST sensitivity, speciﬁcity, positive predictive value (PPV;
prediction of antibiotic resistance) and negative predictive value
(NPV; prediction of antibiotic susceptibility) were calculated for
all samples, and for samples containing enterobacteria only or
non-fermenters only.
Sample size was calculated on the basis of the width of the
95% CI of DAST sensitivity. We calculated that 80 samples
would be sufﬁcient to demonstrate a DAST sensitivity of 99%
with a 95% CI of 96.8–100.
Patient characteristics
Age, sex, unit of admission, Simpliﬁed Acute Physiology Score II
score on admission to the ICU, length of ICU stay before VAP,
as well as antibiotic treatments received before CAST results
were recorded. Empirical therapy was initiated following the
guidelines for the management of adults with VAP speciﬁed byfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 468.e1–468.e6
TABLE 1. Prevalence rates of antibiotic resistance in
enterobacteria and non-fermenters isolated from respiratory
samples using the conventional method
Antibiotics tested
Enterobacteriaa
(n [ 50)
Non-fermentersb
(n [ 42)
n (%) n (%)
Ticarcillin 35 (70.0) 23 (54.8)
468.e3 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIthe American Thoracic Society for all patients [6], and the
treatment was adjusted accordingly when the CAST results
were available.
Potential inﬂuence of DAST results on antibiotic
treatments
For the purpose of analysis, initial treatments of VAP episodes
were classiﬁed as follows: (i) inadequate antibiotic therapy
requiring adaptation, (ii) adequate but broad-spectrum antibi-
otic therapy requiring de-escalation and (iii), adequate initial
therapy requiring neither adaptation nor de-escalation after
DAST.
We analysed the changes that could have been made in the
antibiotic treatment if the DAST results had been made avail-
able to the clinicians 24 h after sampling. Initial antibiotic
therapy was considered adequate when the VAP-associated
bacteria were susceptible to the given antibiotic. In the case
of treatment with a combination of β-lactam plus aminoglyco-
side, only susceptibility to the β-lactam was taken into account
during the adequacy evaluation. De-escalation was considered
when carbapenem had been administered even though the
GNB were found to be susceptible to other β-lactam classes of
antibiotics by DAST and when piperacillin/tazobactam or cef-
tazidime treatment had been administered, even though the
GNB were susceptible to piperacillin or ticarcillin. In all other
instances, including absence of microbiologically conﬁrmed
VAP, lack of change in status was considered relevant. The
number of carbapenem patient-days that could have been saved
was also calculated.
Ethics
According to French laws, this study did not raise any ethical
issues because the DAST results were not communicated to
the physician in charge of the patient and, therefore, did not
inﬂuence patient care. The study was conducted in compliance
with the Standards for the Reporting of Diagnostic accuracy
studies recommendations and the Quality Assessment of
Diagnostic Accuracy Studies tool was used to review the
diagnostic accuracy of the study [14,15].Ticarcillin/clavulanate 24 (48.0) 20 (47.6)
Piperacillin 35 (70.0) 19 (45.2)
Piperacillin/tazobactam 18 (36.0) 19 (45.2)
Cefoxitin 19 (38.0) – –
Cefotaxime 16 (32.0) – –Results
Ceftazidime 16 (32.0) 10 (23.8)
Cefepime 13 (26.0) – –
Aztreonam 16 (32.0) 24 (51.1)
Imipenem 1 (2.0) 20 (47.6)
Meropenem – – 20 (47.6)
Gentamicin 13 (26.0) 26 (61.9)
Amikacin 6 (12.0) 13 (31.0)
Nalidixic acid 17 (34.0) – –
Oﬂoxacin 16 (32.0) 38 (90.5)
Ciproﬂoxacin – – 19 (45.2)
aIncludes 16 Enterobacter sp., 16 Escherichia coli, 7 Klebsiella sp., 7 Proteus sp., 2
Serratia sp. and 2 Citrobacter sp.
bIncludes 35 Pseudomonas aeruginosa, 6 Stenotrophomonas maltophilia and 1
Acinetobacter baumannii.Patients
Eighty-ﬁve samples that tested positive for GNB upon direct
smear examination from 76 patients with suspected VAP were
included in the study. The median age of the patients was 65
years (interquartile range (IQR) 55–75 years). The sex ratio
was 2.6. The median Simpliﬁed Acute Physiology Score II at
admission was 50 (IQR 43–66). Of the 76 patients, 64.5%Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect(n = 49) were hospitalized in the M-ICU, 18.4% (n = 14) in the
S-ICU and 17.1% (n = 13) in the CS-ICU. The median length of
stay in the ICU before VAP was suspected was 10 days (IQR
4–21 days).
Sample results
Seventy-eight (91.8%) of the 85 samples analysed met VAP
microbiological deﬁnitions upon culture. Sixty-two (79.5%)
were mono-microbial and 16 (20.5%) had two species, resulting
in a total of 94 GNB, including 35 (37.2%) Pseudomonas aeru-
ginosa, 16 (16%) Enterobacter sp., 16 (17%) Escherichia coli, 7
(7.4%) Klebsiella sp., 7 (7.4%) Proteus sp., 6 (6.4%) Steno-
trophomonas maltophilia, 2 (0.2%) Serratia sp., 2 (0.2%) Cit-
robacter sp., 2 (0.2%) Haemophilus inﬂuenzae and 1 (0.1%)
Acinetobacter baumannii. Enterobacteria and non-fermenters
were highly resistant to antibiotics; 36%, 32% and 2% of
enterobacteria and 45.2%, 23.8% and 47.6% of non-fermenters,
were resistant to piperacillin/tazobactam, ceftazidime and imi-
penem, respectively (Table 1).
Overall, DAST results were available for 73/85 samples
(85.9%). In seven samples (8.2%), no bacteria or low bacterial
counts below the positivity cut-off were detected upon culture;
these samples were classiﬁed as ‘absence of VAP’ or ‘VAP
without microbiological conﬁrmation’. In two samples (2.4%),
H. inﬂuenzae, which does not grow on Mueller–Hinton agar,
was present in signiﬁcant counts. Finally, in three samples
(3.5%), bacterial growth was not conﬂuent enough to enable
reading of the inhibition diameter (two P. aeruginosa and one
mixture of E. coli and Proteus mirabilis).
Overall, the sensitivity and NPVs of the DAST results
(n = 73) were 100% for all strains and antibiotics tested, exceptious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 468.e1–468.e6
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Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infor aminoglycosides. The sensitivity and NPVs were 97.1% (95%
CI 93.3−101) and 97.4% (95% CI 93.7–101), respectively, for
gentamicin and 88.9% (95% CI 81.7–96.1) and 96.4% (95% CI
92.1–100.7), respectively, for amikacin. Speciﬁcity and PPVs,
ranged from 82.9% (95% CI 74.2–91.5) to 100%, and 86.4%
(95% CI 78.5–94.2) to 100%, respectively (Table 2).
For enterobacteria, sensitivity and NPVs of DAST were
100% for all antibiotics tested, except for aminoglycosides.
Sensitivity and NPV were 91.7% (95% CI 82.5–100.8) and
95.7% (95% CI 88.9–102.4), respectively, for gentamicin and
66.7% (95% CI 51.1–82.3) and 93.6% (95% CI 85.4–101.7),
respectively, for amikacin. Speciﬁcity and PPVs ranged from
68.8% (95% CI 53.5–84.1) to 100%, and 79.2% (95% CI
65.7–92.6) to 100%, respectively (Table 2).
For non-fermenters, sensitivity and NPVs were 100% for all
tested antibiotics including aminoglycosides; speciﬁcity and
PPVs varied from 88.9% (95% CI 78–99.8%) to 100% and 80%
(95% CI 66.1–93.9%) to 100%, respectively.
In one sample, DAST revealed the presence of Enterobacter
cloacae, with high cephalosporinase expression levels, whereas
with CAST, only low cephalosporinase expression levels were
detected.
Potential inﬂuence of DAST results on antibiotic
treatments
If the DAST results had been made available to the physician, the
antibiotic regimens could have been optimized 24 h earlier in 35
(41.2%) cases. Initial antibiotic therapy was ineffective in nine
cases (10.6%), including ﬁve in which imipenem was used
empirically, although the VAP was caused by an imipenem-
resistant strain of P. aeruginosa. In the remaining 26 (30.6%)
cases, de-escalation would have been possible earlier, mostly
because carbapenem had been used empirically (17/26, 65.4%),
whereas the causative bacteria were susceptible to other drugs
(Table 3). Overall, use of DAST results would have saved 17
carbapenem patient-days. For three patients, including one
without antibiotic therapy (considered as colonized) and twowho
died the day after the respiratory samples were obtained, DAST
results would have been useless, requiring no treatment change.DiscussionOur study revealed that DAST, when performed in a stan-
dardized manner according to the results of direct examination,
performed excellently compared with CAST in the diagnosis of
the antibiotic susceptibility of VAP-causing GNB. DAST, com-
bined with mass spectrometry, might help to optimize antibiotic
therapy 24 h earlier in as many as 41% of ICU patients with
suspected VAP.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 468.e1–468.e6
TABLE 3. Potential antibiotic changes after direct antimicrobial susceptibility testing (DAST) results
Initial antibiotic therapy n Change for inadequacy (n) De-escalation (n) No change (n)
Amoxicillin/clavulanate acid ± aminoglycoside 6 0 0 6
Piperacillin/tazobactam ± aminoglycoside 17 1 8 8
Third-generation cephalosporin ± aminoglycoside 9 2 1 6
Carbapanem ± aminoglycoside 32 5 14 13
Carbapenem + othersa 11 1 3 7
Othersb 9 0 0 9
No treatment 1 0 0 1
Total (%) 85 (100%) 9 (10.6%) 26 (30.6%) 50 (58.8%)
aOthers: colimycin + aminoglycoside (n = 3), ciproﬂoxacin (n = 3), colimycin (n = 2), aztreonam (n = 2), ciproﬂoxacin + co-trimoxazole (n = 1).
bOthers: ciproﬂoxacin + colimycin + aminoglycoside (n = 2), ceftazidime + colimycin (n = 1), aztreonam + colimycin ± aminoglycoside (n = 2),
piperacillin (n = 1), aztreonam + co-trimoxazole (n = 1), ticarcillin/clavulanic acid + co-trimoxazole (n = 1), tigecycline + co-trimoxazole (n = 1).
468.e5 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIObtaining antimicrobial susceptibility results usually takes no
less than 48–72 h using CAST, even if bacterial identiﬁcation is
performed using mass spectrometry. We demonstrated here
that DAST provided, within 24 h, results comparable to those
obtained with CAST. DAST is employed in many laboratories to
determine antibiotic susceptibility of GNB from positive blood
cultures [16–18]. However, performing DAST on positive
blood cultures is easier than testing respiratory samples because
the former generally involve a single pathogen and the inocula
are less heterogeneous [19]. In this study, we developed a
method to test lower respiratory samples by DAST based on the
density of GNB observed upon direct smear examination. Pre-
vious studies in which DAST was performed on respiratory
samples showed good concordance with CAST. In these studies,
the heterogeneous nature of the inoculum was overcome by
using E-test strips, which are inoculum-tolerant systems
[10–12,20]. However, the number of antibiotics that can be
tested using E-tests is limited, and the method is more expensive
than disc diffusion. In one study, in which the disc diffusion
method was employed to perform DAST, only three clinically
relevant antibiotics (piperacillin/tazobactam, meropenem and
ciproﬂoxacin) were tested [11]. In our study, we combined the
main advantage of disc diffusion (the fact that a large number of
antimicrobial agents can be tested simultaneously; we tested 16
different antibiotics) with a standardized inoculum based on
direct smear examination. DAST failed to provide interpretable
results in only three (3.5%) samples from conﬁrmed VAP cases.
Notably, in contrast to previous studies, we used mass spec-
trometry for all bacterial identiﬁcations irrespective of the AST
method used (CAST or DAST). This aided the analysis of DAST
results, particularly in the case of mixed cultures. Moreover,
DAST enabled the detection of resistant mutants present in low
counts, which would have been missed by CAST, as shown in at
least one of our patients, who tested positive for an Enterobacter
cloacae strain [21]. Moreover, in contrast to previous studies, we
did not use comparison agreement methods to analyse the re-
sults of DAST and CAST in this study. Because we chose to
assess the diagnostic performances by calculating the sensitivity,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectspeciﬁcity and predictive values of DAST versus CAST, the re-
sults could be used to analyse the therapeutic decisions. NPVs,
predicting susceptibility of GNB to antibiotics, were high for
almost all the agents tested in the study.
Use of DAST results might hasten treatment optimization by
at least 24 h in up to 40% of GNB VAP episodes. We assessed
the clinical impact of DAST and demonstrated a potential effect
on antimicrobial misuse, both in terms of adequacy and earlier
de-escalation of broad-spectrum antibiotic therapy. Early
optimal antibiotic therapy is essential for successful manage-
ment of VAP, because inadequate antibiotic therapy is associ-
ated with increased mortality [22]. The initial antibiotic therapy
was inadequate in as many as 10.6% of VAP patients analysed in
the study in spite of the fact that we followed recognized
recommendations for treatment. In these cases, early avail-
ability of DAST information might have led to improved opti-
mization of antibiotic therapy earlier. Moreover, in 30.6% of the
cases, de-escalation would have been possible earlier. Because
broad-spectrum antibiotics, i.e. carbapenems, are often used
for initial empiric therapy, multidrug-resistant strains frequently
emerge in ICUs. In a previous study, we demonstrated that
exposure to imipenem for just 1–3 days is associated with a
ﬁve-fold increase in the risk of imipenem resistance in ICU
patients [8]. Resistance to carbapenem, leaving very few ther-
apeutic options, continues to increase worldwide, and must be
controlled. In this study, we demonstrated that 17 carbapenem-
days could have been saved using the DAST method.
However, there are some limitations to our study. First, the
study was monocentric, and patients or bacterial ecology from
different hospitals might be different. We tried to overcome
this limitation by including patients from three different ICUs.
Second, the evidence of clinical beneﬁt of DAST was based on a
simulation and needs to be conﬁrmed in a prospective study,
where the DAST results are made available to the clinicians.
Third, we used methods that have not been assessed with
regards to quality standards, which is now required in clinical
laboratories. Such an assessment has to be performed before
routine use of DAST.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 468.e1–468.e6
CMI Le Dorze et al. Direct antimicrobial susceptibility testing in VAP 468.e6In summary, a simple combination of DAST and mass
spectrometry for the analysis of lower respiratory samples
from patients with suspected VAP provided valuable data within
24 h of sampling. This might aid the early optimization of
empirical antimicrobial treatment in cases of severe infections
such as VAP.
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